According to IMARC Group's latest research report, titled "Triple-negative Breast Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033," Triple-negative breast cancer (TNBC) is a form of cancer that causes due to the absence of receptors, including estrogen, progesterone and human epidermal growth factor receptor 2 (HER2). These receptors are proteins that are generally found on the surface of cells that help to control the cell’s growth. It is more likely to spread beyond the breast than other types of breast cancer and is commonly found in individuals that are suffering from specific gene mutations. Some of the popular treatment options available for TNBC include chemotherapy, radiation, and surgery and can also be treated with immunotherapy, which involves the utilization of drugs to boost the body’s own immune system to fight cancer.
The growing prevalence of triple-negative breast cancer among the masses majorly drives the global market. Along with this, the introduction of advanced biopsy techniques aiding several aspects of breast cancer management, including early relapse detection, longitudinal monitoring of disease progression, and prognosis prediction, is significantly supporting the market. In addition, the growing emphasis on patient-centric care and the adoption of personalized medicines is impacting the market favorably. With the increasing reliance on genetic testing for triple-negative breast cancer to determine the most effective treatment plan for the patient, this is providing a thrust to the market.
Get Free Sample Copy of Report at – https://www.imarcgroup.com/triple-negative-breast-cancer-market/requestsample
Key Market Segmentation:
Time Period of the Study:
Base Year: 2022
Historical Period: 2017-2022
Market Forecast: 2023-2033
Analysis Covered Across Each Country:
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the triple-negative breast cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the triple-negative breast cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
In-Market Drugs:
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
Drug Overview
Mechanism of Action
Regulatory Status
Clinical trial Results
Regulatory Status
Countries Covered:
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Key Highlights of the Report:
Market Performance
Market Outlook
Porter’s Five Forces Analysis
Market Drivers and Success Factors
SWOT Analysis
Value Chain
Comprehensive Mapping of the Competitive Landscape
Comments